The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors

Clinical Immunology

Volumn 137, Issue 3, 2010, Pages 347-356

  Jiang, Fan ^a   Chen, Wei ^a   Yi, Kejia ^b   Wu, Zhiqiang ^a   Si, Yiling ^a   Han, Weidong ^a   Zhao, Yali ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Beijing Science Technology and Management College   (China)

Author keywords

Catechin; HIV integrase; Inhibitor

Indexed keywords

CATECHIN; CATECHIN GALLATE; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; GALLOCATECHIN GALLATE; INTEGRASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CATECHIN; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PYRROLIDINONES;

EID: 78149280033     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.08.007     Document Type: Article

References (39)

1. Deeks S.G., Kar S., Gubernick S.I., Kirkpatrick P. Raltegravir. Nat. Rev. Drug Discov. 2008, 7:117-118.
2. Pommier Y., Johnson A.A., Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4:236-248.
3. Lataillade M., Kozal M.J. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDs 2006, 20:489-501.
4. Johnson A.A., Marchand C., Pommier Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr. Top. Med. Chem. 2004, 4:1059-1077.
5. Croxtall J.D., Lyseng-Williamson K.A., Perry C.M. Raltegravir. Drugs 2008, 68:131-138.
6. Lennox J.L., DeJesus E., Lazzarin A., Pollard R.B., Madruga J.V., Berger D.S., Zhao J., Xu X., Williams-Diaz A., Rodgers A.J., Barnard R.J., Miller M.D., DiNubile M.J., Nguyen B.Y., Leavitt R., Sklar P. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806.
7. Croxtall J.D., Keam S.J. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009, 69:1059-1075.
8. da Silva D., Van Wesenbeeck L., Breilh D., Reigadas S., Anies G., Van Baelen K., Morlat P., Neau D., Dupon M., Wittkop L., Fleury H., Masquelier B. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regiment. J. Antimicrob. Chemother. 2010, 65:1262-1269.
9. Serrao E., Odde S., Ramkumar K., Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:1-14.
10. Ikeda I. Multifunctional effects of green tea catechins on prevention of the metabolic syndrome. Asia Pac. J. Clin. Nutr. 2008, 17:273-274.
11. Song J.M., Lee K.H., Seong B.L. Antiviral effect of catechins in green tea on influenza virus. Antiviral. Res. 2005, 68:66-74.
12. Cabrera C., Artacho R., Giménez R. Beneficial effects of green tea-a review. J. Am. Coll. Nutr. 2006, 25:79-99.
13. Demeule M., Michaud-Levesque J., Annabi B., Gingras D., Boivin D., Jodoin J., Lamy S., Bertrand Y., Béliveau R. Green tea catechins as novel antitumor and antiangiogenic compounds. Curr. Med. Chem. Anticancer Agents 2002, 2:441-463.
14. Nance C.L., Siwak E.B., Shearer W.T. Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy. J. Allergy Clin. Immunol. 2009, 123:459-465.
15. Yamaguchi K., Honda M., Ikigai H., Hara Y., Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral. Res. 2002, 53:19-34.
16. Fassina G., Buffa A., Benelli R., Varnier O.E., Noonan D.M., Albini A. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS 2002, 16:939-941.
17. Moore P.S., Pizza C. Observations on the inhibition of HIV-1 reverse transcriptase by catechins. Biochem. J. 1992, 288:717-719.
18. Williamson M.P., McCormick T.G., Nance C.L., Shearer W.T. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J. Allergy Clin. Immunol. 2006, 118:1369-1374.
19. Kawai K., Tsuno N.H., Kitayama J., Okaji Y., Yazawa K., Asakage M. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J. Allergy Clin. Immunol. 2003, 112:951-957.
20. Maignan S., Guilloteau J.P., Liu Q.Z., Mella C.C., Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282:359-368.
21. Goldgur Y., Craigie R., Cohen G.H., Fujiwara T., Yoshinaga T., Fujishita T., Sugimoto H., Endo T., Murai H., Davies D.R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl Acad. Sci. USA 1999, 96:13040-13043.
22. De Luca L., Pedretti A., Vistoli G., Barreca M.L., Villa L., Monforte P. Analysis of the full-length integrase-DNA complex by a modified approach for DNA docking. Biochem. Biophys. Res. Commun. 2003, 310:1083-1088.
23. Schames J.R., Henchman R.H., Siegel J.S., Sotriffer C.A., Ni H., McCammon J.A. Discovery of a novel binding trench in HIV integrase. J. Med. Chem. 2004, 47:1879-1881.
24. Schüttelkopf, A,.W., van Aalten D.M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:1355-1363.
25. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Computational. Chemistry. 2010, 31:455-461.
26. Iorga B., Herlem D., Barré E., Guillou C. Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach. J. Mol. Model. 2006, 12:366-372.
27. XpressBio life science products. HIV-1 integrase assay kit (version 1.1). http://www.biocat.com/bc/pdf/integrasev1.1_090213.pdf.
28. Serrao E., Odde S., Ramkumar K., Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:1-14.
29. Barreca M.L., Iraci N., De Luca L., Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem 2009, 4:1446-1456.
30. Chen X., Tsiang M., Yu F., Hung M., Jones G.S., Zeynalzadegan A., et al. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into binding modes of potent integrase inhibitors. J. Mol. Biol. 2008, 380:504-519.
31. Lins R.D., Adesokan A., Soares T.A., Briggs J.M. Investigations on human immunodeficiency virus type 1 integrase/DNA binding interactions via molecular dynamics and electrostatics calculations. Pharmacol. Ther. 2000, 85:123-131.
32. Greenwald, J,., Le V., Butler S.L., Bushman F.D., Choe S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry 1999, 38:8892-8898.
33. Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464:232-236.
34. Bessong, P,.O,., Obi, C,.L,., Andréola M,.L,., Rojas, L,.B,., Pouységu L., Igumbor E., et al. Evaluation of selected South African medicinal plants for inhibitory properties against human immunodeficiency virus type 1 reverse transcriptase and integrase. J. Ethnopharmacol. 2005, 99:83-91.
35. Chow H.H., Cai Y., Hakim I.A., Crowell J.A., Shahi F., Brooks C.A., Dorr R.T., Hara Y., Alberts D.S. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res. 2003, 9:3312-3319.
36. Ullmann U., Haller J., Decourt J.D., Girault J., Spitzer V., Weber P. Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10days repeated dosing in healthy volunteers. Int. J. Vitam. Nutr. Res. 2004, 74:269-278.
37. Bode A.M., Dong.Z. Epigallocatechin 3-gallate and green tea catechins: united they work, divided they fail. Cancer Prev. Res. 2009, 2:514-517. (Phila Pa).
38. Feng W.Y. Metabolism of green tea catechins: an overview. Curr. Drug Metab. 2006, 7:755-809.
39. Marchand C., Maddali K., Métifiot M., Pommier Y. HIV-1 IN inhibitors: 2010 update and perspectives. Curr. Top. Med. Chem. 2009, 9:1016-1037.